- The study investigated immune activation differences between Orca-T and unmanipulated peripheral blood stem cell grafts after allogeneic hematopoietic stem cell transplantation.
- Researchers performed single-cell RNA sequencing and flow cytometry on peripheral blood from 51 HLA-matched patients longitudinally.
- Orca-T recipients showed increased effector memory CD4+ T cells at 3 weeks, persisting through 6 months post-transplantation.
- The authors concluded that a novel CD4+CD25-FOXP3+Helios+ T-cell subset, enriched early in Orca-T patients, may predict long-term immune activation.
- This T-cell subset could serve as an early biomarker for immune reconstitution and potential GVHD or relapse risk after cellular therapy.
Unpacking Immune Dynamics After Cellular Therapies for Hematologic Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a curative path for many hematologic malignancies, yet its success is frequently limited by graft-versus-host disease (GVHD) [1, 2]. To mitigate this complication, engineered cell products like Orca-T have been developed. Orca-T is an allogeneic T-cell immunotherapy that enriches for regulatory T cells (Tregs), a cell type critical for establishing immune tolerance, while preserving graft-versus-leukemia effects [1, 3, 4, 5]. The clinical potential of this strategy is significant, with one trial reporting a 78.0% one-year chronic GVHD-free survival rate in Orca-T recipients compared to 38.4% with standard prophylaxis [6]. Despite these outcomes, the specific immunological shifts that occur early after infusion, and how they differ from standard transplants, have not been fully elucidated [7, 8]. A recent study now provides a high-resolution map of the early immune environment following Orca-T, identifying a distinct T-cell population that may influence long-term immune reconstitution.
Investigating Immune Responses to Cellular Grafts
A central question for clinicians is how the immune activation profile of a patient receiving Orca-T differs from that of a patient receiving a standard unmanipulated peripheral blood stem cell (PBSC) graft. To address this, researchers initiated a longitudinal study to compare the post-transplant immune landscapes produced by these two distinct cellular therapies. Understanding these differences is clinically vital, as the patterns of early immune reconstitution can influence the subsequent risk of infection, GVHD, and disease relapse.
The investigation included 51 HLA-matched patients being treated for leukemia, who received either the Orca-T product or a conventional PBSC graft. To capture the dynamic evolution of the immune system, peripheral blood samples were collected at multiple time points, from 3 weeks to 1 year post-transplant. The researchers then applied a powerful dual-analysis strategy. They used single-cell RNA sequencing (scRNA-seq), a technique that examines the gene expression of thousands of individual cells to reveal their function and identity, alongside flow cytometry, a well-established method for quantifying specific cell populations based on protein markers on their surface and inside the cell.
Early Immune Signatures with Orca-T
The study's initial analysis revealed a distinct immune profile emerging shortly after Orca-T infusion. Compared to recipients of standard PBSC grafts, patients who received Orca-T showed increased frequencies of effector memory CD4+ T cells just 3 weeks after transplantation. This subset of T cells is responsible for long-term immunosurveillance and can mount a rapid response to familiar antigens. The finding suggests an early establishment of a mature memory T-cell compartment. This was not a fleeting change; the elevation of these effector memory cells persisted for at least 6 months after treatment, indicating a durable alteration of the immune system by the Orca-T product.
To understand the molecular basis for these changes, the researchers used single-cell RNA sequencing data from the 3-week time point. This detailed genetic analysis uncovered a subtle but significant finding: increased expression of the genes FOXP3 and Helios within CD4+CD25- T conventional cells (Tcon) in Orca-T recipients. FOXP3 is the canonical master transcription factor for regulatory T cells, while Helios helps stabilize their suppressive function. Finding these regulatory markers expressed in conventional T cells, which are typically non-regulatory, was unexpected. Using flow cytometry to look for the corresponding proteins, the team confirmed the presence of a higher frequency of this unique CD4+CD25-FOXP3+Helios+ Tcon population at 3 weeks post-treatment in patients receiving Orca-T, validating the existence of this previously uncharacterized cell subset.
Characterizing a Regulatory-Like T-Cell Subset
Having identified this unique T-cell population, the investigators sought to define its functional role. Their analysis showed that the CD4+CD25-FOXP3+Helios+ T conventional cell subset possessed a regulatory-like phenotype. This means that although these cells do not fit the classic definition of a regulatory T cell (Treg), they express key molecular machinery associated with immune suppression. The emergence of such a population could contribute to the lower rates of GVHD observed with Orca-T by helping to control excessive immune activation from other T cells.
A key finding with direct clinical relevance was the predictive capacity of this cell subset. The frequency of these regulatory-like Tcon at 3 weeks post-transplant was found to correlate significantly with the frequencies of activated CD4+ and CD8+ T cells measured at 3 months. This is important because activated CD4+ and CD8+ T cells are the primary mediators of both the desired graft-versus-leukemia effect and the detrimental effects of GVHD. Crucially, this correlation held true for patients regardless of whether they received Orca-T or a standard PBSC graft, suggesting this cell population may be a universal indicator of downstream immune tone after allo-HSCT.
Implications for Immune Monitoring and Prognosis
This study's primary contribution is the identification and characterization of a specific T-cell population, the CD4+CD25-FOXP3+Helios+ T conventional cell (Tcon), that is enriched very early after cellular therapy for leukemia. This enrichment was most pronounced in patients receiving Orca-T, an immunotherapy designed specifically to leverage regulatory T cells to prevent the primary nonrelapse complication of allo-HSCT, graft-versus-host disease.
The discovery of this cell subset has direct implications for post-transplant patient management. The findings suggest that this regulatory-like Tcon population may be predictive of long-term immune activation following both Orca-T and standard PBSC infusions. Because the early abundance of these cells correlates with the level of broader T-cell activation at 3 months, monitoring this population could offer a valuable early biomarker. For the practicing clinician, quantifying these cells shortly after transplant could one day help stratify patients at risk for aberrant immune reconstitution, potentially allowing for earlier intervention to manage the delicate balance between preventing GVHD, clearing residual malignancy, and maintaining defense against infection.
References
1. Meyer E, Salhotra A, Gandhi A, et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2025. doi:10.1182/blood.2025031313
2. Bader CS, Pavlova A, Lowsky R, et al. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD. Blood Advances. 2023. doi:10.1182/bloodadvances.2023011625
3. Dittmar DJ, Pielmeier F, Strieder N, et al. Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease. Nature Communications. 2024. doi:10.1038/s41467-024-47575-z
4. Chen Y, Xu Y, Wu D. Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting. Experimental Hematology and Oncology. 2023. doi:10.1186/s40164-023-00425-y
5. Zuber J, Kaminski H. The 2025 Nobel Prize in Physiology or Medicine Honors the Immune Peacekeepers. Transplant International. 2025. doi:10.3389/ti.2025.15767
6. Meyer E, Salhotra A, Gandhi A, et al. Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial. Blood. 2025. doi:10.1182/blood-2025-2477
7. Bader CS, Killian S, Iliopoulou BP, et al. Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy. Blood. 2026. doi:10.1182/blood.2025031545
8. Gandhi A, Purdum A, Pavlova A, et al. Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T). Blood. 2025. doi:10.1182/blood-2025-2473